Jinyu Bio-Technology Co Ltd (600201) - Total Liabilities
Based on the latest financial reports, Jinyu Bio-Technology Co Ltd (600201) has total liabilities worth CN¥1.09 Billion CNY (≈ $159.62 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Jinyu Bio-Technology Co Ltd strategic investment ratio to see how much of total assets are deployed in long-term investments.
Jinyu Bio-Technology Co Ltd - Total Liabilities Trend (1995–2025)
This chart illustrates how Jinyu Bio-Technology Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see balance sheet size of Jinyu Bio-Technology Co Ltd.
Jinyu Bio-Technology Co Ltd Competitors by Total Liabilities
The table below lists competitors of Jinyu Bio-Technology Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Luenmei Quantum Co Ltd
SHG:600167
|
China | CN¥4.37 Billion |
|
Eastern Communications Co Ltd A
SHG:600776
|
China | CN¥944.95 Million |
|
Galapagos NV ADR
NASDAQ:GLPG
|
USA | $119.06 Million |
|
A.F.P. Provida
SN:PROVIDA
|
Chile | CL$206.75 Billion |
|
Target Hospitality Corp
NASDAQ:TH
|
USA | $284.40 Million |
|
L&F Co. Ltd
KQ:066970
|
Korea | ₩2.24 Trillion |
|
Hubei Yihua Chemical Industry Co Ltd
SHE:000422
|
China | CN¥32.63 Billion |
|
Sichuan Expressway Co Ltd
SHG:601107
|
China | CN¥45.33 Billion |
Liability Composition Analysis (1995–2025)
This chart breaks down Jinyu Bio-Technology Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 600201 net asset quality score to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.21 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.20 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Jinyu Bio-Technology Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Jinyu Bio-Technology Co Ltd (1995–2025)
The table below shows the annual total liabilities of Jinyu Bio-Technology Co Ltd from 1995 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥1.06 Billion ≈ $155.22 Million |
-21.39% |
| 2024-12-31 | CN¥1.35 Billion ≈ $197.44 Million |
+10.81% |
| 2023-12-31 | CN¥1.22 Billion ≈ $178.18 Million |
+17.12% |
| 2022-12-31 | CN¥1.04 Billion ≈ $152.14 Million |
-0.38% |
| 2021-12-31 | CN¥1.04 Billion ≈ $152.73 Million |
+2.79% |
| 2020-12-31 | CN¥1.02 Billion ≈ $148.58 Million |
+41.65% |
| 2019-12-31 | CN¥716.78 Million ≈ $104.89 Million |
-34.28% |
| 2018-12-31 | CN¥1.09 Billion ≈ $159.60 Million |
-9.54% |
| 2017-12-31 | CN¥1.21 Billion ≈ $176.42 Million |
+102.61% |
| 2016-12-31 | CN¥595.04 Million ≈ $87.07 Million |
+23.55% |
| 2015-12-31 | CN¥481.62 Million ≈ $70.48 Million |
+3.02% |
| 2014-12-31 | CN¥467.50 Million ≈ $68.41 Million |
+8.76% |
| 2013-12-31 | CN¥429.83 Million ≈ $62.90 Million |
-46.62% |
| 2012-12-31 | CN¥805.23 Million ≈ $117.83 Million |
+9.68% |
| 2011-12-31 | CN¥734.19 Million ≈ $107.44 Million |
-1.40% |
| 2010-12-31 | CN¥744.64 Million ≈ $108.96 Million |
+14.89% |
| 2009-12-31 | CN¥648.15 Million ≈ $94.84 Million |
+24.87% |
| 2008-12-31 | CN¥519.05 Million ≈ $75.95 Million |
-11.53% |
| 2007-12-31 | CN¥586.66 Million ≈ $85.85 Million |
+75.50% |
| 2006-12-31 | CN¥334.28 Million ≈ $48.92 Million |
-28.42% |
| 2005-12-31 | CN¥467.02 Million ≈ $68.34 Million |
+4.96% |
| 2004-12-31 | CN¥444.93 Million ≈ $65.11 Million |
+15.72% |
| 2003-12-31 | CN¥384.49 Million ≈ $56.26 Million |
+35.67% |
| 2002-12-31 | CN¥283.40 Million ≈ $41.47 Million |
+15.89% |
| 2001-12-31 | CN¥244.53 Million ≈ $35.78 Million |
+8.06% |
| 2000-12-31 | CN¥226.29 Million ≈ $33.11 Million |
+59.19% |
| 1999-12-31 | CN¥142.15 Million ≈ $20.80 Million |
+34.03% |
| 1998-12-31 | CN¥106.06 Million ≈ $15.52 Million |
-12.11% |
| 1997-12-31 | CN¥120.67 Million ≈ $17.66 Million |
-7.31% |
| 1996-12-31 | CN¥130.19 Million ≈ $19.05 Million |
-3.02% |
| 1995-12-31 | CN¥134.24 Million ≈ $19.64 Million |
-- |
About Jinyu Bio-Technology Co Ltd
Jinyu Bio-technology Co., Ltd. engages in the research and development, production, and sale of veterinary biological products in China and internationally. The company's products focus on preventing porcine mycoplasmal pneumonia, pseudorabies, highly pathogenic avian influenza, brucellosis, and other Class I, II, and III animal diseases. It also provides pig vaccines, swine foot-and-mouth diseas… Read more